Analysis Tools
mortality/aging
|
• about of 50% of mice die within the first 9 weeks of age with enlarged lymphoid organs and severe anemia
• the remaining mice die by 25 weeks of age from inflammatory bowel disease
|
digestive/alimentary system
|
• rarely observed
|
|
• colon epithelium shows loss of goblet cells
(J:15223)
• loss of mucin is observed in goblet cells
(J:29999)
|
|
• all mice that do not die within the first 9 weeks after birth exhibit diarrhea
|
|
• prominent epithelial regeneration with crypt branching and dysplasia near areas of inflammation
(J:15223)
• crypt hyperplasia and unusual branching is observed
(J:29999)
|
|
• frequently occurres in the large intestine
|
|
• ulcers occur in the large intestine, with pronounced thickening of the bowel wall
|
|
• frequent occurrence among mice whom live past 9 weeks of age
(J:15223)
• occasional occurrence among mice whom live past 9 weeks of age
(J:29999)
|
|
• all mice that do not die within the first 9 weeks after birth develop an inflammatory bowel disease that is similar to the human disease ulcerative colitis
(J:15223)
• infiltrating lymphocytes sometimes form nodules
(J:15223)
• mice bred in a germ-free facility do not display any histopathological signs of colitis
(J:15223)
• mice bred under specific pathogen free conditions do not develop any clinical signs of colitis but histological and immunological examinations show the beginning of inflammatory processes in mice that are 17-20 weeks of age
(J:15223)
• occurs in all mice that survive past 9 weeks of age, with thickening of large intestinal wall
(J:29999)
• mice kept under a specific pathogen free environment develop colitis when immunized with an antigen that activates CD4 T cells
(J:37220)
|
immune system
|
• proliferative response of splenocytes to anti-CD3 antibody is only 16% of wt controls
• poor proliferative response to anti-CD3 antibody is partially rescued by addition of cytokines including IL-2, IL-4, IL-7
• there is reduced proliferation to allogenic leukocytes
|
|
• all mice that do not die within the first 9 weeks after birth develop an inflammatory bowel disease that is similar to the human disease ulcerative colitis
(J:15223)
• infiltrating lymphocytes sometimes form nodules
(J:15223)
• mice bred in a germ-free facility do not display any histopathological signs of colitis
(J:15223)
• mice bred under specific pathogen free conditions do not develop any clinical signs of colitis but histological and immunological examinations show the beginning of inflammatory processes in mice that are 17-20 weeks of age
(J:15223)
• occurs in all mice that survive past 9 weeks of age, with thickening of large intestinal wall
(J:29999)
• mice kept under a specific pathogen free environment develop colitis when immunized with an antigen that activates CD4 T cells
(J:37220)
|
|
• occurs in the 50% of mice that die prematurely
|
|
• decreased apoptosis in thymus upon injection with anti-CD3 antibody
|
|
• of cells in the bone marrow
|
|
• 10 fold greater amounts of IFN gamma were made by thymocytes from immunized mutant mice as measured by an in vitro assay
• low levels of the Th2 cytokine IL-4 were made compared to the large level made by wt thymocytes
• however, treatment with an IL-12 neutralizing antibody normalized Th1cytokine levels
|
|
• there is a drastic reduction in the colon
|
|
• percentage of these cells is increased (11.2% vs 3.7%) in the thymus when mice are immunized with a CD4 T cell activating antigen
|
|
• percentage of these cells is decreased (47.0% vs 86.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
|
|
• of cells in the bone marrow
|
|
• percentage of these cells is increased (41.8% vs 20.9.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
• however, treatment with an IL-12 neutralizing antibody normalized SP cell numbers
|
|
• increased number (5-100 fold) are found in diseased colon
(J:15223)
• T cells expressing the CD8 alpha-beta heterodimer predominate over CD8 alpha-alpha T cells
(J:39981)
|
|
• decreased percentage of these cells are found in the colon epithelium
|
|
• B cells from lymph nodes have a larger size and incorporate more BrdU, indicating a faster proliferation rate
|
|
• the proliferation of T cells in the colon is twice that of wild-type controls
(J:15223)
• 2-10 fold higher using in vivo incorporation of BrdU, which indicates a faster proliferation rate
(J:16662)
|
|
• increased activation of thymocytes 7 days after immunization with a CD4 T cell activating antigen, as measured by expression of CD69 and Icam1
(J:37220)
• however, treatment with an IL-12 neutralizing antibody normalized the percentage of activated thymocytes
(J:37220)
• in vitro proliferation is reduced in presence of concanavalin A or anti-CD3 antibody
(J:39989)
|
|
• there is delayed class switching from IgM to IgG after infection with vesicular stomatitis virus
|
|
• drastic elevation in secretion by B cells found in the colon
|
|
• levels are 10 fold higher than those observed in wild-type mice
|
|
• drastic elevation in secretion of IgG1 by B cells found in the colon
(J:15223)
• levels of IgG1 are increased 100 fold
(J:16662)
• levels of IgG1 are drastically increased to levels above 2700 ug/ml
(J:39989)
|
|
• levels of IgG2a are also elevated
|
|
• levels of IgG2b are also elevated
|
|
• 3 to 9 fold reduction in killing of NK susceptible target cells as measured by chromium release assay
|
|
• there is an impaired ability to induce Ig class switching in B cells after infection with vesicular stomatitis virus
(J:15573)
• increased cytotoxic effectiveness of CD4 T cells isolated from the colon
(J:39981)
• unable to induce IgM secretion from activated B cells in an in vitro assay
(J:39989)
• however, IgM levels are in vivo are normal
(J:39989)
|
|
• enhanced target cell killing by intraepithelial lymphocytes T cells (IEL) and lamina propia lymphocytes of the large intestine
• enhanced target cell killing by intraepithelial lymphocytes T cells (IEL) of the small intestine
|
|
• there is a three fold reduction of target cell killing by primary T cells in a chromium release assay
(J:15573)
• no target cell killing by previously stimulated T cells in a chromium release assay
(J:15573)
• there is reduced killing of allogeneic tumor cells in an in vitro assay
(J:26198)
• footpad swelling is reduced 6-10 days after infection with lymphocytic choriomeningitis virus
(J:26861)
|
|
• increased 3-10 fold in size as compared to control littermates
|
|
• expression occurs in high number of colon epithelial cells
|
|
• despite reduced cytotoxic T cell activity, mice still clear lymphocytic choriomeningitis virus within nine days of infection
|
|
• graft rejection of allogeneic pancreatic islet cells is delayed by 11 days compared to controls
|
growth/size/body
|
• occurs in the 50% of mice that die prematurely
|
hematopoietic system
|
• proliferative response of splenocytes to anti-CD3 antibody is only 16% of wt controls
• poor proliferative response to anti-CD3 antibody is partially rescued by addition of cytokines including IL-2, IL-4, IL-7
• there is reduced proliferation to allogenic leukocytes
|
|
• occurs in the 50% of mice that die prematurely
|
|
• severe anemia is found in 50% of mice that die prematurely
(J:15223)
• occurs in mice 24 weeks of age
(J:29999)
|
|
• decreased apoptosis in thymus upon injection with anti-CD3 antibody
|
|
• of cells in the bone marrow
|
|
• 10 fold greater amounts of IFN gamma were made by thymocytes from immunized mutant mice as measured by an in vitro assay
• low levels of the Th2 cytokine IL-4 were made compared to the large level made by wt thymocytes
• however, treatment with an IL-12 neutralizing antibody normalized Th1cytokine levels
|
|
• there is a drastic reduction in the colon
|
|
• percentage of these cells is increased (11.2% vs 3.7%) in the thymus when mice are immunized with a CD4 T cell activating antigen
|
|
• percentage of these cells is decreased (47.0% vs 86.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
|
|
• of cells in the bone marrow
|
|
• percentage of these cells is increased (41.8% vs 20.9.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
• however, treatment with an IL-12 neutralizing antibody normalized SP cell numbers
|
|
• increased number (5-100 fold) are found in diseased colon
(J:15223)
• T cells expressing the CD8 alpha-beta heterodimer predominate over CD8 alpha-alpha T cells
(J:39981)
|
|
• decreased percentage of these cells are found in the colon epithelium
|
|
• B cells from lymph nodes have a larger size and incorporate more BrdU, indicating a faster proliferation rate
|
|
• the proliferation of T cells in the colon is twice that of wild-type controls
(J:15223)
• 2-10 fold higher using in vivo incorporation of BrdU, which indicates a faster proliferation rate
(J:16662)
|
|
• increased activation of thymocytes 7 days after immunization with a CD4 T cell activating antigen, as measured by expression of CD69 and Icam1
(J:37220)
• however, treatment with an IL-12 neutralizing antibody normalized the percentage of activated thymocytes
(J:37220)
• in vitro proliferation is reduced in presence of concanavalin A or anti-CD3 antibody
(J:39989)
|
|
• there is delayed class switching from IgM to IgG after infection with vesicular stomatitis virus
|
|
• drastic elevation in secretion by B cells found in the colon
|
|
• levels are 10 fold higher than those observed in wild-type mice
|
|
• drastic elevation in secretion of IgG1 by B cells found in the colon
(J:15223)
• levels of IgG1 are increased 100 fold
(J:16662)
• levels of IgG1 are drastically increased to levels above 2700 ug/ml
(J:39989)
|
|
• levels of IgG2a are also elevated
|
|
• levels of IgG2b are also elevated
|
|
• 3 to 9 fold reduction in killing of NK susceptible target cells as measured by chromium release assay
|
|
• there is an impaired ability to induce Ig class switching in B cells after infection with vesicular stomatitis virus
(J:15573)
• increased cytotoxic effectiveness of CD4 T cells isolated from the colon
(J:39981)
• unable to induce IgM secretion from activated B cells in an in vitro assay
(J:39989)
• however, IgM levels are in vivo are normal
(J:39989)
|
|
• enhanced target cell killing by intraepithelial lymphocytes T cells (IEL) and lamina propia lymphocytes of the large intestine
• enhanced target cell killing by intraepithelial lymphocytes T cells (IEL) of the small intestine
|
|
• there is a three fold reduction of target cell killing by primary T cells in a chromium release assay
(J:15573)
• no target cell killing by previously stimulated T cells in a chromium release assay
(J:15573)
• there is reduced killing of allogeneic tumor cells in an in vitro assay
(J:26198)
• footpad swelling is reduced 6-10 days after infection with lymphocytic choriomeningitis virus
(J:26861)
|
endocrine/exocrine glands
|
• colon epithelium shows loss of goblet cells
(J:15223)
• loss of mucin is observed in goblet cells
(J:29999)
|
|
• frequently occurres in the large intestine
|
|
• increased activation of thymocytes 7 days after immunization with a CD4 T cell activating antigen, as measured by expression of CD69 and Icam1
(J:37220)
• however, treatment with an IL-12 neutralizing antibody normalized the percentage of activated thymocytes
(J:37220)
• in vitro proliferation is reduced in presence of concanavalin A or anti-CD3 antibody
(J:39989)
|
behavior/neurological
|
• occurs in mice 24 weeks of age
|
cardiovascular system
|
• rarely observed
|
homeostasis/metabolism
amyloidosis
(
J:15223
)
|
• predominately in liver, spleen, and kidneys
|
cellular
|
• colon epithelium shows loss of goblet cells
(J:15223)
• loss of mucin is observed in goblet cells
(J:29999)
|
|
• B cells from lymph nodes have a larger size and incorporate more BrdU, indicating a faster proliferation rate
|
|
• the proliferation of T cells in the colon is twice that of wild-type controls
(J:15223)
• 2-10 fold higher using in vivo incorporation of BrdU, which indicates a faster proliferation rate
(J:16662)
|
|
• proliferative response of splenocytes to anti-CD3 antibody is only 16% of wt controls
• poor proliferative response to anti-CD3 antibody is partially rescued by addition of cytokines including IL-2, IL-4, IL-7
• there is reduced proliferation to allogenic leukocytes
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| inflammatory bowel disease | DOID:0050589 |
OMIM:PS266600 |
J:15223 | |
